In8Bio (INAB) Treasury Shares (2020 - 2021)
In8Bio's (INAB) quarterly Treasury Shares came in at $10.0 million in Q2 2021, up 135.26% year-over-year from $4.2 million in Q2 2020, and little changed quarter-over-quarter from $10.0 million in Q1 2021.
Powered by 
Analysis
In8Bio (INAB) Treasury Shares (2020 - 2021) Analysis & Trends
In8Bio has disclosed Treasury Shares across 2 years of filings, most recently posting $10.0 million for Q2 2021.
- In Q2 2021, Treasury Shares rose 135.26% year-over-year to $10.0 million; the TTM figure through Jun 2021 stood at $10.0 million (up 135.26% YoY), while the FY2020 annual figure was $10.0 million, changed N/A from the prior year.
- Treasury Shares came in at $10.0 million for Q2 2021 at In8Bio, roughly flat from $10.0 million in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $10.0 million in Q4 2020 to a low of $4.2 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 17.69 Mn |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | - |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - | - |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | 655,642.00 |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | - |
| 10 | In8Bio | 21.58 Mn | 21.58 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 9.99 Mn |
| Jun 30, 2021 | 9.99 Mn |
| Mar 31, 2021 | 9.99 Mn |
| Mar 31, 2021 | 9.99 Mn |
| Dec 31, 2020 | 9.99 Mn |
| Dec 31, 2020 | 9.99 Mn |
| Sep 30, 2020 | 9.76 Mn |
| Sep 30, 2020 | 9.76 Mn |
| Jun 30, 2020 | 4.25 Mn |
| Jun 30, 2020 | 4.25 Mn |